---
title: "For companies: reach biotech investors"
url: "https://aibio.space/for-companies/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "Publish your own posts and articles on your company page for US$169 a month, or send news, corrections and replies free. Our coverage is never for sale."
---

What investors find

- A profile page for each of 2,820 listed companies, built for search engines and AI assistants.
- A full desk for covered companies: news, pipeline, cash, dated catalysts and investor questions.
- Full stories and desks for free members, who sign up with their email address.

What we never do

- Sell coverage. A Company Channel never changes our stories, desk views, Investor Rank or corrections.
- Publish company posts without a clear label saying who wrote them and that the company pays for the channel.

For companies

# Get your company in front of investors

aibio.space is an investor news site about public biotech and pharma companies. If your company is listed, it already has a profile here. Until a company takes a Company Channel, our editors manage its page. These are the ways to make sure investors see your news, your updates and the right contact.

Send us your news

Press releases, 8-Ks, trial results, financings, leadership changes. Editors read every submission and write it up when it is news for investors. We always link your primary source.

Publish on your own page: US$169 a month

Post your releases, articles, videos and investor updates on your company page, under your name, with a Company Channel. Clearly labeled as company content. Cancel any time.

Claim your company page

Confirm you speak for the company. We verify your work email, list your IR contact on your profile and send your news to the right editor. Free.

Name your investor relations contact

Tell us who handles IR and media. We list it on your desk and use it for comment requests, so investors and editors reach the right person.

Keep your profile accurate

Your profile shows ticker, exchange, ISIN and other listings. If something is out of date, send the filing or exchange page and we fix it.

Answer a story

Disagree with an article or a desk view? Send your response. If it adds facts or a fair counterpoint, we publish it, linked from the piece.

## Find your company

Search by name or ticker to open your profile or desk.

Or browse [all 2,820 companies by country](https://aibio.space/companies/).

## How a company gets a full desk

Editors choose which companies get a full desk, based on reader interest and how much public information there is to check. A desk is written only after an editor has gone through the company's filings, pipeline and cash, with every figure linked to its source. You can ask for a desk through the [company update form](https://aibio.space/reputation/#update). Asking does not guarantee one, and a desk cannot be bought.

## What makes a submission easy to use

Send the link to the primary source: the press release, the SEC or exchange filing, the ClinicalTrials.gov record or the journal paper. Say what is new and when it happened. Name a person who can answer questions. Submissions with a public source are written up fastest.

[Send a company update](https://aibio.space/reputation/#update)

Read our [disclosures and method](https://aibio.space/disclosures/) and the [corrections policy](https://aibio.space/disclosures/#corrections). Questions: contact@aibio.space.

---
Source page: https://aibio.space/for-companies/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "For companies: reach biotech investors", 2026-10-31, https://aibio.space/for-companies/